Thyroid Gland Medullary Carcinoma — Trials

Thyroid Gland Medullary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

105 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 25
Recruiting: 8
Ph III recruiting: 1
Growth YoY: —
Industry share: 32%
Top sponsor: Eli Lilly and Company
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04211337	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531)	active not recruiting	Phase 3	291	Loxo Oncology, Inc.INDUSTRY	20	Mar 19, 2026	clinicaltrials

Data updated 22 days agoSource updated Mar 19, 2026source: clinicaltrials